Urokinase plasminogen activator receptor (uPA-R): One potential characteristic of metastatic phenotypes in minimal residual tumor disease

Cancer Research

Volumn 57, Issue 7, 1997, Pages 1394-1399

  Allgayer, Heike ^a   Heiss, Markus Maria ^a   Riesenberg, Rainer ^a   Grützner, Klaus Uwe ^a   Tarabichi, Anwar ^a   Babic, Rudolf ^b   Schildberg, Friedrich Wilhelm ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Institute of Pathology and Cytology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CYTOKERATIN; UROKINASE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BONE MARROW; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; RECEPTORS, CELL SURFACE; STOMACH NEOPLASMS;

EID: 0030984295     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Moll, R., Franke, W. W., Schiller, D. L., Geiger, B., and Krepler, R. The catalogue of human cytokeratins: pattern of expression in normal epithelia, tumors and cultured cells. Cell, 31: 11-24, 1982.
2. Allgayer, H., Heiss, M. M., Riesenberg, R., Babic, R., Jauch, K. W., and Schildberg, F. W. Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA, receptor and CK18: investigation of sensitivity and specificity of an immunogold/alcaline phosphatase double staining protocol J. Histochem. Cytochem., 45: 203-212, 1997.
3. Pantel, K., Schlimok, G., Angstwurm, M., Weckermann, D., Schmaus, W., Gath, H., Passlick, B., Izbicki, J. R., and Riethmüller, G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J. Hematother., 3: 165-173, 1994.
4. Lindemann, F., Schlimok, G., Dirschedl, P., Wine, J., and Riethmüller, G. Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet, 340: 685-689, 1992.
5. Pantel, K., Schlimok, G., Braun, S., Kutter, D., Lindemann, F., Schaller, G., Funke, L, Izbicki, J., and Riethmüller, G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl. Cancer Inst., 85: 1419-1423, 1993.
6. Schlimok, G., Funke, I., Holzmann, B., Göttlinger, G., Schmidt, G., Häuser, H., Swierkot, S., Warnecke, H. H., Schneider, B., Koprowski, H., and Riethmüller, G. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1-A monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 84: 8672-8676, 1987.
7. Jauch, K. W., Heiss, M. M., Grützner, K. U., Funke, I., Pantel, K., Babic, R., Eissner, H. J., Riethmüller, G., and Schildberg, F. W. The prognostic significance of early disseminated tumor cells in bone marrow of patients with gastric cancer. J. Clin. Oncol., 14: 1810-1817, 1996.
8. Pantel, K., Izbicki, J. R., Angstwurm, M., Braun, S., Passlick, B., Karg, O., Thetter, O., and Riethmüller, G. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res., 53: 1027-1031, 1993.
9. Berger, U., Bettelheim, R., Mansi, J. L., Easton, D., Coombes, R. C., and Neville, A. M. The relationship between micrometastasis in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am. J. Clin. Pathol., 90: 1-6, 1988.
10. Moss, T. J., Reynold, C. P., Sather, H. N., Romansky, S. G., Hammond, G. D., and Seeger, R. C. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N. Engl. J. Med., 324: 219-226, 1991.
11. Heiss, M. M., Allgayer, H., Gruetzner, K. U., Funke, I., Babic, R., Jauch, K. W., and Schildberg, F. W. Individual development and uPA-R-expression of disseminated tumor cells in bone marrow: a reference to early systemic disease in solid cancer. Nat. Med., 1: 1035-1039, 1995.
12. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays, 15: 105-111, 1993.
13. Moller, L. B. Structure and function of the urokinase receptor. Blood Coagul. & Fibrinolysis, 4: 293-303, 1993.
14. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
15. Duffy, M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin. & Exp. Metastasis, 10: 145-155, 1992.
16. Dvorak, H. F. Tumors: wounds that do not heal. N. Engl. J. Med. 315: 1650-1659, 1986.
17. Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., and Andreasen, P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
18. Heiss, M. M., Babic, R., Allgayer, R, Grützner, K. U., Jauch, K. W., Löhrs, U., and Schildberg, F. W. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol., 13: 2084-2093, 1995.
19. Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hoefler, H., and Graeff, H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res, Treat., 24: 195-208, 1993.
20. Foekens, J. A., Schmitt, M., van Putten, W. L., Peters, H. A., Kramer, M. D., Jänicke, F., and Klijn, J. G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol., 12: 1648-1658, 1994.
21. Jänicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A., and Graeff, H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res., 54: 2527-2530, 1994.
22. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Dano, K., and Brünner, N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
23. Loos, J. A., and Roos, D. Ficoll-isopaque gradients for the determination of density distributions of human blood lymphocytes and other reticulo-endothelial cells. Exp. Cell Res., 86: 333-341, 1974.
24. Cordell, J. L., Falini, B., Erber, W. N., Ghosh, A. K., Abdulaziz, Z., MacDonald, S., Pulford, K. A. F., Stein, H., and Mason, D. Y. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alcaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J. Histochem. Cytochem., 32: 219-229, 1984.
25. Paget, S. Distribution of secondary growths in cancer of the breast Lancet, 1: 571, 1989.
26. Fidler, I., and Kripke, M. L. Metastasis results from pre-existing variant cells within a malignant tumor. Science (Washington DC), 797: 893-895, 1977.
27. Allgayer, H., Heiss, M. M., Babic, R., Grützner, K, U., Jauch, K. W., Löhrs, U., and Schildberg, F. W. Expression of tumor-associated proteases and their inhibitors in gastric cancer: impact on prognosis. Proc. Am. Assoc. Cancer Res., 36: 93, 1995.
28. Schmitt, M., Jänicke, F., and Graeff, H. Tumor-associated proteases. Fibrinolysis, 6(Suppl.): 3-26, 1992.
29. Jankun, J., Merrick, H. W., and Goldblatt, P. J. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. Cell. Biochem., 53: 135-144, 1993.
30. Bastholm, L., Nielsen, M. H., DeMey, J., Dano, K., Brünner, N., Hoyer-Hansen, G., Ronne, E., and Elling, F. A. D. Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotech. & Histochem., 69: 61-67, 1994.
31. Ossowski, L., Clunie, G., Masucci, M. T., and Blasi, F. In vivo paracrine interaction between urokinase and ist receptor: effect on tumor cell invasion. J. Cell Biol., 115: 1107-1112, 1991.
32. Stahl, A., and Mueller, B. M. A. D. Binding of urokinase to ist receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res., 54: 3066-3071, 1994.
33. Eder, H., Sliutz, G. Schiebl, L, Kolbl, H., and Zeillinger, R. Quantification of uPA-receptor expression in human breast cancer cell lines by cRT-PCR. J. Exp. Clin. Cancer Res., 13(Suppl. 3): 286, 1994.
34. Hudziak, R. M., Schlessinger, S., and Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cell. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
35. Davidwatine, D. P., Israel, A., and Kourilsky, P. The regulation and expression of MHC class I genes. Immunol. Today, 11: 286-292, 1990.
36. Hämmerling, G., Maschek, U., Sturmhöfel, K., and Momburg, F. Regulation and functional role of MHC expression on tumors. Prog. Immunol., 7: 1071-1078, 1989.
37. Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R., Funke, L, and Riethmüller, G. Frequent down-regulation of MHC class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res., 51: 4712-4715, 1991.
38. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.